Literature DB >> 9815651

Comparative evaluation of angiogenesis assessment with anti-factor-VIII and anti-CD31 immunostaining in non-small cell lung cancer.

A Giatromanolaki1, M I Koukourakis, D Theodossiou, K Barbatis, K O'Byrne, A L Harris, K C Gatter.   

Abstract

Anti-Factor VIII vessel immunostaining has been widely used in the detection of angiogenesis in non-small cell lung cancer and other tumors. Several new antibodies have shown a higher sensitivity, and anti-CD31 has recently been proposed to be the standard for microvessel study. In the present study, we comparatively evaluated the two antibodies in 134 cases of early operable non-small cell lung cancer. The F8/86 (anti-Factor VIII-associated antigen) and JC70 (anti-CD31) MoAbs were used in paraffin-embedded material. Eye appraisal of vascular grade (VG) and microvessel score (MS) was performed by three experienced pathologists. Different cutoff points were used for the analysis of VG and MS correlation with nodal involvement, overall survival, and thymidine phosphorylase expression. Intra- and interobserver variability was minimal for both antibodies. MS and VG were significantly correlated with each other. However, 54 and 22% of cases with high anti-CD31 VG or high MS, respectively, had low vascularization on anti-Factor VIII assessment. Anti-CD31 scoring was significantly associated with nodal involvement and overall survival for all cutoff points considered, which was not verified for anti-Factor VIII staining. VG was the most significant indicator of nodal involvement and survival for both antibodies. Tumors with high VG by anti-CD31 but low or medium VG by anti-Factor VIII behaved as tumors of high neoangiogenesis, defining a poor prognosis (P = 0.005) despite the failure of anti-factor VIII antibody to highlight intense neoangiogenesis. Anti-CD31 MS significantly associated with thymidine phosphorylase overexpression (P = 0.01), whereas no correlation was found for anti-Factor VIII counting. It was concluded that anti-CD31 microvessel immunostaining has several advantages over anti-Factor VIII, being a more sensitive method for highlighting small, immature microvessels or single endothelial cells. This could be of importance in revealing possible correlation of tumor angiogenesis with metastatic behavior, prognosis, or angiogenic factor overexpression. Vascular grading was the best method for neovascularization assessment, efficiently defining groups of tumors with aggressive clinical course.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9815651

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  28 in total

1.  In vivo fluorescence imaging in the second near-infrared window with long circulating carbon nanotubes capable of ultrahigh tumor uptake.

Authors:  Joshua T Robinson; Guosong Hong; Yongye Liang; Bo Zhang; Omar K Yaghi; Hongjie Dai
Journal:  J Am Chem Soc       Date:  2012-06-15       Impact factor: 15.419

2.  Imaging proliferation of ¹⁸F-FLT PET/CT correlated with the expression of microvessel density of tumour tissue in non-small-cell lung cancer.

Authors:  Wenfeng Yang; Yongming Zhang; Zheng Fu; Xiaorong Sun; Dianbin Mu; Jinming Yu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-05-12       Impact factor: 9.236

3.  Immunohistochemistry in the evaluation of neovascularization in tumor xenografts.

Authors:  D Wang; C R Stockard; L Harkins; P Lott; C Salih; K Yuan; D Buchsbaum; A Hashim; M Zayzafoon; R W Hardy; O Hameed; W Grizzle; G P Siegal
Journal:  Biotech Histochem       Date:  2008-06       Impact factor: 1.718

4.  Neo-angiogenesis in locally advanced squamous cell head and neck cancer correlates with thymidine phosphorylase expression and p53 nuclear oncoprotein accumulation.

Authors:  A Giatromanolaki; G Fountzilas; M I Koukourakis; P Arapandoni; V Theologi; S Kakolyris; V Georgoulias; A L Harris; K C Gatter
Journal:  Clin Exp Metastasis       Date:  1998-10       Impact factor: 5.150

5.  Biodistribution of the ¹⁸F-FPPRGD₂ PET radiopharmaceutical in cancer patients: an atlas of SUV measurements.

Authors:  Ryogo Minamimoto; Mehran Jamali; Amir Barkhodari; Camila Mosci; Erik Mittra; Bin Shen; Frederick Chin; Sanjiv Sam Gambhir; Andrei Iagaru
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-06-11       Impact factor: 9.236

6.  Effect of terazosin on tissue vascularity and apoptosis in transitional cell carcinoma of bladder.

Authors:  Anastasios Tahmatzopoulos; Chad A Lagrange; Li Zeng; Bonnie L Mitchell; William T Conner; Natasha Kyprianou
Journal:  Urology       Date:  2005-05       Impact factor: 2.649

7.  A critical role for I kappaB kinase alpha in the development of human and mouse squamous cell carcinomas.

Authors:  Bigang Liu; Eunmi Park; Feng Zhu; Tracie Bustos; Jinsong Liu; Jianjun Shen; Susan M Fischer; Yinling Hu
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-01       Impact factor: 11.205

8.  The prognostic value of platelet endothelial cell adhesion molecule-1 in non-small-cell lung cancer patients.

Authors:  Bo-hua Kuang; Xi-zhi Wen; Ya Ding; Rui-qing Peng; Pei-qiang Cai; Meng-qing Zhang; Feng Jiang; Xiao-shi Zhang; Xing Zhang
Journal:  Med Oncol       Date:  2013-03-15       Impact factor: 3.064

9.  Pilot prospective evaluation of (18)F-FPPRGD2 PET/CT in patients with cervical and ovarian cancer.

Authors:  Ryogo Minamimoto; Amer Karam; Mehran Jamali; Amir Barkhodari; Sanjiv Sam Gambhir; Oliver Dorigo; Andrei Iagaru
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-27       Impact factor: 9.236

10.  Differential assessment of angiogenic activity and of vascular survival ability (VSA) in breast cancer.

Authors:  Alexandra Giatromanolaki; Efthimios Sivridis; Constantinos Simopoulos; Alexandros Polychronidis; Kevin C Gatter; Adrian L Harris; Michael I Koukourakis
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.